Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

New Trends to Treat Muscular Atrophy: Systematic Review

Version 1 : Received: 30 June 2023 / Approved: 30 June 2023 / Online: 30 June 2023 (14:49:48 CEST)

How to cite: German, I.J.S.; Torres, K.; Andreo, J.C.; Shindo, J.; Dallantonia, C.; Haber, L.; Detregiachi, C.R.P.; Araujo, A.; Guiguer, E.L.; Girio, R.; Bueno, P.; Souza, M.; Rocha, M.; Barbalho, S.M.; Shinohara, A. New Trends to Treat Muscular Atrophy: Systematic Review. Preprints 2023, 2023062260. https://doi.org/10.20944/preprints202306.2260.v1 German, I.J.S.; Torres, K.; Andreo, J.C.; Shindo, J.; Dallantonia, C.; Haber, L.; Detregiachi, C.R.P.; Araujo, A.; Guiguer, E.L.; Girio, R.; Bueno, P.; Souza, M.; Rocha, M.; Barbalho, S.M.; Shinohara, A. New Trends to Treat Muscular Atrophy: Systematic Review. Preprints 2023, 2023062260. https://doi.org/10.20944/preprints202306.2260.v1

Abstract

Epicatechin has been described as a polyphenol compound that promotes skeletal muscle restructuring, by expressing muscle regulation factors, activation of satellite cells and modulation of the main pathways associated with catabolism. However, the literature shows contrasting results of therapeutic effects and treatment protocols. Thus, the aim of this systematic review was to analyze the current literature addressing the molecular mechanism and clinical protocol of epicatechin on skeletal muscular atrophy in humans and animals. A search was conducted in PubMed/MEDLINE, Embase, Web of Science, and Cochrane Library databases. The qualitative analysis showed a prevalence of the inhibitory action of epicatechin in myostatin expression and atrogenes FOXO, MAFbx and MuRF1. Epicatechin showed positive effects on increased follistatin and on the activation of the myogenic regulatory factors (Myf5, MyoD and myogenin). In addition, the studies evidenced the impact of epicatechin on the mitochondrias' biosynthesis in muscle fibers, activation of the signaling pathway of AKT/mTOR protein synthesis, and improvement of skeletal musculature performance, particularly when associated with physical training. Epicatechin showed promising clinical applicability through beneficial results under conditions that negatively affect the skeletal musculature. However, there is no protocol standardization allowing to draw more specific conclusions on its therapeutic use.

Keywords

epicatechin; skeletal muscle; muscular atrophy; catechins; myogenic regulatory factors

Subject

Medicine and Pharmacology, Medicine and Pharmacology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.